RaDiCo PID Cohort (RaDiCo-ILD Cohort in English) (RaDiCo-PID)

Institut National de la Santé Et de la Recherche Médicale, France

Status: Enrolling

Conditions: Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse; Paediatric and Adult Patients

Study type: Observational

Funder types: Other

Identifiers

NCT04238871

C15-64

Details and patient eligibility

About

The main objective is to describe the phenotypic features of the paediatric and adult patients with Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse (IIP/PID), at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID.

Full description

The French RaDiCo-PID : Idiopathic Interstitial Pneumopathy registry is an ongoing observational prospective and retrospective cohort with longitudinal long-term follow-up includes pediatric and adult patients with Idiopathic Interstitial Lung Disease (ILD) from the reference and competence centers.

Enrollment: 2,500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest
• Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing
• Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise
• Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol
• Patients affiliated to the "Regime National d'Assurance Maladie"

Exclusion criteria

• Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders
• Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol

Trial design

2,500 participants in 1 patient group

children or adults with Idiopathic Lung Disease